Sab Biotherapeutics, Inc. (SABSW) — SEC Filings
Sab Biotherapeutics, Inc. (SABSW) — 34 SEC filings. Latest: 8-K (Dec 29, 2025). Includes 20 8-K, 6 10-Q, 3 DEF 14A.
View Sab Biotherapeutics, Inc. on SEC EDGAR
Overview
Sab Biotherapeutics, Inc. (SABSW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: On December 29, 2025, SAB Biotherapeutics, Inc. filed an 8-K report. The filing indicates that the company, formerly known as Big Cypress Acquisition Corp. until November 20, 2020, is involved in the biological products sector. The report details information related to warrants exercisable for commo
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 29 neutral, 2 mixed. The dominant filing sentiment for Sab Biotherapeutics, Inc. is neutral.
Filing Type Overview
Sab Biotherapeutics, Inc. (SABSW) has filed 20 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of SABSW's 26 recent filings, 3 were flagged as high-risk, 17 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $30,134,426 |
| EPS | N/A |
| Debt-to-Equity | 0.11 |
| Cash Position | $29,424,708 |
| Operating Margin | N/A |
| Total Assets | $183,448,368 |
| Total Debt | $18,374,019 |
Key Executives
- Samuel J. Reich
- Dr. Steven M. Deitcher
- Dr. David L. R. Gray
- Dr. Jonathan M. Rothberg
Industry Context
SAB Biotherapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel protein-based therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight from agencies like the FDA. Success hinges on innovation, clinical trial outcomes, and the ability to secure substantial funding to advance drug candidates through development and commercialization.
Top Tags
warrants (8) · corporate-governance (8) · Biotechnology (5) · filing (4) · 10-Q (4) · financials (4) · disclosure (3) · shareholder-vote (3) · biotechnology (3) · officer-changes (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Warrant Exercise Price | $11.50 | Price at which warrants can be exercised for common stock. |
| Net Income | $30.1M | for the nine months ended September 30, 2025, a swing from a $22.7M loss in 2024 |
| Gain from Warrant Liabilities | $66.0M | primary driver of net income for the nine months ended September 30, 2025 |
| Proceeds from 2025 PIPE | $168.7M | significant cash infusion from financing activities |
| Cash and Cash Equivalents | $29.4M | as of September 30, 2025, up from $8.9M at December 31, 2024 |
| Accumulated Deficit | $94.0M | decreased from $124.1M at December 31, 2024 |
| Total Stockholders' Equity | $165.1M | increased from $26.0M at December 31, 2024 |
| Research and Development Expenses | $23.6M | for the nine months ended September 30, 2025, an increase from $22.6M in 2024 |
| Net Cash Used in Operating Activities | $27.9M | for the nine months ended September 30, 2025, indicating ongoing operational burn |
| Common Stock Shares Outstanding | 47,606,851 | as of November 10, 2025 |
| Threshold for potential common stock issuance | 19.99% | Issuance upon Series B conversion may exceed this, triggering Nasdaq rules. |
| Increase in shares for 2021 Omnibus Equity Incentive Plan | 24,180,000 | Adds to the maximum number of shares available for participants. |
| Aggregate shares available for 2021 Omnibus Equity Incentive Plan | 31,932,466 | New total after proposed amendment. |
| Current annual evergreen increase for Plan | 10,000,000 | Proposed to be significantly increased. |
| Proposed annual evergreen increase for Plan | 73,750,000 | Massive increase in potential future share issuance. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Sab Biotherapeutics, Inc. (SABSW)?
Sab Biotherapeutics, Inc. has 34 recent SEC filings from Jan 2024 to Dec 2025, including 20 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SABSW filings?
Across 34 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 29 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Sab Biotherapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sab Biotherapeutics, Inc. (SABSW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sab Biotherapeutics, Inc.?
Key financial highlights from Sab Biotherapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SABSW?
The investment thesis for SABSW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sab Biotherapeutics, Inc.?
Key executives identified across Sab Biotherapeutics, Inc.'s filings include Samuel J. Reich, Dr. Steven M. Deitcher, Dr. David L. R. Gray, Dr. Jonathan M. Rothberg.
What are the main risk factors for Sab Biotherapeutics, Inc. stock?
Of SABSW's 26 assessed filings, 3 were flagged high-risk, 17 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Sab Biotherapeutics, Inc.?
Forward guidance and predictions for Sab Biotherapeutics, Inc. are extracted from SEC filings as they are enriched.